Table I.
Clinical and pathological characteristics of patients exhibiting endometrioid type endometrial cancer.
| Lymphadenectomy | |||
|---|---|---|---|
|
|
|||
| Variable | Pelvic, n=97 | Pelvic and para-aortic, n=89 | P-value |
| Median age at surgery, years (IQR) | 55 (49–61) | 59 (53–65) | 0.003 |
| Histologic subtype, n (%) | |||
| Endometrioid, pure | 67 (69.1) | 45 (50.6) | 0.023a |
| Endometrioid, with squamous differentiation | 28 (28.9) | 44 (49.4) | |
| Endometrioid, villoglandular variant | 1 (1.0) | 0 (0.0) | |
| Endometrioid, ciliated cell variant | 1 (1.0) | 0 (0.0) | |
| FIGO stage, n (%) | |||
| IA | 70 (72.2) | 28 (31.5) | <0.001b |
| IB | 23 (23.7) | 23 (25.8) | |
| II | 0 (0.0) | 14 (15.7) | |
| IIIA | 0 (0.0) | 3 (3.4) | |
| IIIC | 4 (4.1) | 19 (21.3) | |
| IV | 0 (0.0) | 2 (2.2) | |
| Risk of recurrence, n (%) | |||
| Low | 57 (58.8) | 21 (23.6) | <0.001a |
| Low-intermediate | 21 (21.6) | 20 (22.5) | |
| High-intermediate | 15 (15.5) | 25 (28.1) | |
| High | 4 (4.1) | 23 (25.8) | |
| Median tumor size, cm (IQR) | 2.8 (1.5–4.0) | 3.5 (2.3–5.0) | 0.002 |
| Peritoneal cytology positive, n (%) | 2 (2.1) | 3 (3.4) | 0.670 |
| Surgery, n (%) | |||
| Laparoscopy | 31 (32.0) | 6 (6.7) | <0.001 |
| Laparotomy | 66 (68.0) | 83 (93.3) | |
| Median lymph nodes removed, n (IQR) | |||
| Pelvic lymph nodes | 22 (18–29) | 26 (21–32) | 0.018 |
| Para-aortic lymph nodes | 0 (0.0) | 14 (9–19) | <0.001 |
| Adjuvant treatment, n (%) | |||
| None | 63 (64.9) | 20 (22.5) | <0.001a |
| Radiotherapy alone | 31 (32.0) | 45 (50.6) | |
| Chemotherapy alone | 0 (0.0) | 2 (2.1) | |
| Chemotherapy and radiotherapy | 2 (2.1) | 15 (16.8) | |
| Unknown | 1 (1.0) | 7 (7.9) | |
| Median follow-up time, months (95% CI) | 39 (38.14–47.13) | 37 (31.88–41.06) | 0.079 |
IQR, interquartile range; FIGO, International Federation of Gynecology and Obstetrics; CI, confidence interval. P-values following the Bonferroni correction were a0.0125 and b0.0083.